Let's TalkLet's TalkThe fastest-growing cash-pay category in medicine, and the most heavily restricted to advertise - where the platform rules decide what the campaign can even say.
Weight loss is the most restricted category most clinics will ever advertise in, and the second problem is that patients leave after four months. We will review your creative against the platform rules that actually get accounts restricted, and model your revenue per patient against how long they genuinely stay.
Local conditions that change the plan, rather than the state name pasted into a template.
GLP-1 interest in Texas is enormous and coverage is patchy - many employer plans exclude weight-loss indications outright. The practical effect is that most of your addressable market is paying out of pocket for a treatment priced like a car payment. That makes price presentation, financing and the monthly-commitment framing the conversion levers, far more than clinical differentiation.
The loudest bidders on these terms are national brands with acquisition budgets that do not need to be profitable this year. A local clinic cannot outspend them and should not try. What it has that they do not is in-person assessment, local lab work and a clinician the patient can sit in front of when something is not working - and that has to be the entire spine of the positioning, not a bullet point.
The economics of a weight-loss programme are decided in months three through nine, not at acquisition. A clinic filling the top of the funnel while patients quietly lapse at month two is buying the same patient repeatedly. The highest-return work here is usually not another campaign - it is the onboarding sequence, the check-in cadence and the side-effect support that keep someone on programme.
The board that governs your advertising depends on the licence you hold, not only on the state. These are the rules that bite in Texas.
FDA warning letters in this category have gone directly at advertising copy - phrases equating a compounded product with an approved one, such as describing it as the same active ingredient as a brand name, as a generic version of one, or as being from the same family. That is marketing language, written by marketers, and it is the specific thing being cited. It does not belong in your ads regardless of who wrote it.
After FDA declared the semaglutide and tirzepatide shortages resolved, the compounding pathways narrowed sharply, with 503A and 503B facilities losing the shortage-based basis for producing copies on stated 2025 deadlines. A campaign promising compounded product on terms your pharmacy can no longer supply creates a compliance problem and a patient-experience one simultaneously. Sourcing should be settled before the media is booked, not after.
22 TAC Chapter 164 governs physician advertising in Texas and reaches false, misleading or deceptive claims and the use of testimonials. Weight loss is a category built on transformation imagery and numbers, which makes it structurally prone to implying typical results from exceptional ones. Texas takes an unusually broad position on testimonials in healthcare advertising, and we build campaigns that do not depend on them.
The same programme as everywhere, run against this state's rules.
The nearest engagement we can point to is the clinic network below - 54,000+ leads, $327K managed, cost per lead down 57%. It was not a weight-loss practice and we are not going to present it as one. The transferable part is scaled acquisition without a collapse in lead quality. The sourcing and advertising-language constraints above are specific to this category right now, and they change faster than any other area we work in.
Read the full case studyThat comparison language is precisely what FDA warning letters in this category have cited - copy equating a compounded preparation with an approved brand, whether by calling it the same active ingredient, a generic version, or part of the same family. We will not write it, and we would remove it from anything inherited. The clinically accurate description of what you actually dispense is both safer and, in our experience, more persuasive to a patient who is already reading carefully.
Treat it as a question for your counsel and your pharmacy before it is a marketing question. FDA declared the semaglutide and tirzepatide shortages resolved, which removed the shortage-based compounding pathway on stated 2025 deadlines, and the enforcement picture has continued to move since. The marketing consequence is simple: we build the campaign around what you can lawfully and reliably supply for the next six months, because a funnel promising something you cannot fill is worse than no funnel.
By selling the thing they structurally cannot. They win on price, convenience and brand recognition, and a local clinic matching them on those terms loses money on every patient. What they cannot offer is a clinician in the room, local labs, and someone accountable when the dose needs changing or the side effects are bad. That is a genuinely different product and it justifies a genuinely different price, but only if the marketing leads with it rather than mentioning it.
Retention at month three and month six, then cost per patient-month rather than cost per enquiry. This category has a long revenue tail and a high lapse rate, and a campaign optimised to cheap first appointments will happily fill your clinic with patients who leave before the programme becomes profitable. We report acquisition and retention on the same page for that reason, even when it makes the acquisition number look worse.
With care, and in Texas with more care than most states. 22 TAC Chapter 164 reaches misleading advertising and the use of testimonials, and Texas takes a notably broad view of what counts in healthcare advertising - broader than practices expect. Transformation imagery also carries the separate risk of implying typical results from an exceptional case. We design these campaigns so they work without depending on testimonials, which is a constraint elsewhere and closer to a requirement here.
The full service, and the neighbouring states we cover.
Which metro, which procedures, and what you are running now. We will tell you honestly whether we can help, and what the board rules mean for it.